Borosil Scientific Limited manufactures laboratory glassware, laboratory instruments, process systems and pharmaceutical primary packaging (ampoules and vials), operating four manufacturing locations in India, offering over 4,000 SKUs and exporting to 90+ countries under brands such as BOROSIL, LabQuest and Borosil Process Sciences, serving pharmaceuticals, research institutions, academia and industrial laboratories.

Q3FY26 consolidated revenue was Rs.121.3 crore (up 19.6% YoY) with consolidated EBITDA at Rs.19.6 crore (16.2% margin) and consolidated PAT of Rs.8.7 crore, reflecting quarter‑level operating leverage; nine‑month consolidated results were muted due to lower Process Systems execution and exceptional items related to restructuring and labour code adjustments.

Borosil Scientific claims market leadership in Indian laboratory glassware (three out of four lab glassware products in India bear the Borosil name), a wide addressable footprint across lab consumables, equipment, process systems and pharma packaging, and a stated medium‑term revenue CAGR target of 12–14% supported by Make‑in‑India tailwinds and export push.

Key near‑term dynamics include strong growth in Lab Consumables and Lab Equipment, volatility in Process Systems execution due to order deferrals, concentration risk with pharmaceuticals representing ~58% of FY25 customers, and opportunity from government initiatives such as Biopharma SHAKTI and China‑plus‑one sourcing that could accelerate exports and higher‑margin product adoption.